Barbara Nicke
Nuvisan, Innovation Campus Berlin, Berlin, Germany
Welcome
RAS oncogenes were considered undruggable for decades. Yet, this situation changed considerably with the development of new drugs targeting different mutant isoforms culminating in the approval of the first RAS-targeting drug in 2021. Nevertheless, a better understanding of the basic principles of RAS signaling may guide the development of improved therapeutic options.
The goal of this symposium is to highlight recent advances in RAS biology and novel therapeutic strategies to foster scientific discussions as to how the field can advance to address future challenges. At the same time, we plan to nurture dialogue between clinicians, preclinical as well as industrial researchers to envision how current research may guide future clinical practice.
We are inviting basic researchers, clinicians, and pharmaceutical scientists to join us in Salamanca, Spain, in September 2023, at our symposium Targeting RAS: new avenues and challenges.
Targeting RAS
Symposium
13th – 15th
September
2023
Welcome
Targeting RAS, new challenges and avenues. RAS oncogenes were considered undruggable for decades.
Yet, this situation changed considerably with the development of new drugs targeting different mutant isoforms culminating in the approval of the first RAS-targeting drug in 2021.
Nevertheless, a better understanding of the basic principles of RAS signaling may guide the development of improved therapeutic options.
The goal of this symposium is to highlight recent advances in RAS biology and novel therapeutic strategies to foster scientific discussions as to how the field can advance to address future challenges.
At the same time, we plan to nurture dialogue between clinicians, preclinical as well as clinical industrial researchers to envision how current research may guide future clinical practice.
Program
13th september
14th september
15th september
13th september
13 September 2023
09:00
09:30
10:00
11:45
12:15
15:00
16:45
17:45
14th september
14 September 2023
09:30
10:00
12:45
15:30
17:00
17:30
Speakers
Channing J. Der
University of North Carolina (UNC), Chapel Hill, USA
Chiara Ambrogio
University of Torino, Torino, Italy
Christina Kiel
University of Pavia, Pavia, Italy
Christopher Counter
Duke University Medical Center, North Carolina, USA
Colin Lindsay
Christie NHS Foundation Trust, University of Manchester, Manchester, UK
Dafna Bar Sagi
NYU Langone Health, New York, USA
Daniel Abankwa
University of Luxembourg
David Tuveson
Cold Spring Harbor Laboratory, New York, USA
Ernest Nadal
Ernest Nadal (Catalan Institute of Oncology (ICO); Bellvitge Biomedical Research Institute (IDIBELL); L'Hospitalet, Barcelona, Spain)
Frank McCormick
National Cancer Institute RAS Initiative (Frederick National Laboratory for Cancer Research, Frederick, MD) & University of California, San Francisco (UCSF), Helen Diller Family Comprehensive Cancer Center, USA.
Ian Prior
University of Liverpool, Liverpool, UK
James Christensen
Mirati Therapeutics, San Diego, USA
Julian Downward
The Francis Crick Institute, London, UK
Kairbaan Hodivala-Dilke
Barts Cancer Institute, London, UK
Kevan Shokat
Howard Hughes Medical Institute, Maryland, USA & University of California San Francisco (UCSF), San Francisco, USA & University of California (UC Berkeley), Berkeley, USA.
Luis Paz-Ares
Hospital Universitario 12 de Octubre, Madrid, Spain
Mariano Barbacid
Centro de Investigaciones Oncológicas (CNIO), Madrid, Spain
Mathew Holderfield
Revolution Medicines, Redwood City, USA
Owen Sansom
Beatson Institute for Cancer Research, Glasgow. UK
Pablo Rodríguez-Viciana
University College London (UCL), London, UK
Pedro Beltran
Bridge Bio, Palo Alto, USA
Piero Crespo
IBBTEC, University of Cantabria, Santander, Spain
Rati Verma
Amgen, Thousand Oaks, California, USA
René Bernards
Netherlands Cancer Institute, Amsterdam, Netherlands
Ruth Nussinov
National Cancer Institute (NCI), Frederick, USA
Shiva Malek
Novartis Institutes for Biomedical Research, Boston, USA
Silve Vicent
CIMA, University of Navarra, Pamplona, Spain
Udai Banerji
The Institute of Cancer Research, London, UK
Walter Kolch
Systems Biology Ireland, University College Dublin, Dublin, Ireland
Xosé R. Bustelo
Centro de investigación del Cáncer (CIC), Salamanca, Spain
Yibing Shan
D. E. Shaw Research, New York, USA
Registration
Event Location
Palacio de Congresos Salamanca
Cuesta de Oviedo, S/N, 37008 Salamanca
Suitable for conferences, performances and shows.
Subscribe
to our Newsletter
For direct information about the symposium and to find out about the latest news.
Targeting RAS – New challenges and avenues has been made possible thanks to:
Do you want to enjoy and benefit from the knowledge of world-renowned researchers?
Any questions?
Ask us
If you need additional information or would like to know any specific details, please contact us.
